The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
New Multiple Sclerosis Phenotypic Classification
Abstract
Background: In 1996, the clinical course of multiple sclerosis (MS) was characterized as relapsing-remitting, primary progressive, secondary progressive or progressive relapsing. Since then, an increased understanding of MS and its pathology prompted a re-examination of these clinical phenotypes. Main recommendations of the 2013 revisions are provided herein. Summary: Clinically isolated syndrome has been added, and progressive relapsing MS has been eliminated, from the clinical course descriptions. All forms of MS should be further subcategorized as either active or non-active. Active MS is defined as the occurrence of clinical relapse or the presence of new T2 or gadolinium-enhancing lesions over a specified period of time, preferably at least one year. An additional subcategory for patients with progressive MS differentiates between those who have shown signs of disability progression over a given time period and those who have remained stable. The term ‘worsening' is recommended to describe patients whose disease is advancing for any reason, whereas ‘disease progression' should be reserved for those with progressive disease who are truly progressing (as opposed to worsening from a relapse). The term ‘benign' should be used with caution as the course of MS can worsen at any time, even after many years of apparent stability. Key Messages: Newer characterizations of MS phenotypes include a consideration of disease activity (based on the clinical relapse rate and imaging findings) and disease progression. Accurate clinical course descriptions are useful for communication, prognostication, clinical trial design and to guide everyday clinical decision-making. © 2014 S. Karger AG, Basel
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Self-citationDefining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationHawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Cited by
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
The prevalence of MS in the United States: A population-based estimate using health claims data
Wallin, M. T., Culpepper, W. J., Campbell, J. D., Nelson, L. M., Langer-Gould, A., Marrie, R. A., Cutter, G. R., Kaye, W. E., Wagner, L., Tremlett, H., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007035 · Cited by 1,098
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Berer, K., Gerdes, L. A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., Liu, C., Klotz, L., Stauffer, U., Baranzini, S. E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711233114 · Cited by 933
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G.-S., Bartley, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04432-7 · Cited by 908
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Filippi, M., Rocca, M. A., Ciccarelli, O., De Stefano, N., Evangelou, N., Kappos, L., Rovira, A., Sastre-Garriga, J., Tintorè, M., Frederiksen, J. L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00393-2 · Cited by 880
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis
Absinta, M., Maric, D., Gharagozloo, M., Garton, T., Smith, M. D., Jin, J., Fitzgerald, K. C., Song, A., Liu, P., Lin, J.-P., et al. (2021) · Nature · doi:10.1038/s41586-021-03892-7 · Cited by 768
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
Benedict, R. H. B., Amato, M. P., DeLuca, J., & Geurts, J. J. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30277-5 · Cited by 764
New insights into the burden and costs of multiple sclerosis in Europe
Kobelt, G., Thompson, A., Berg, J., Gannedahl, M., Eriksson, J., the MSCOI Study Group, & Platform, T. E. M. S. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517694432 · Cited by 733
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Multiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Differential diagnosis of suspected multiple sclerosis: a consensus approach
Miller, D., Weinshenker, B., Filippi, M., Banwell, B., Cohen, J., Freedman, M., Galetta, S., Hutchinson, M., Johnson, R., Kappos, L., et al. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508096878 · Cited by 642
Self-citationIdentification of tissue-specific cell death using methylation patterns of circulating DNA
Lehmann-Werman, R., Neiman, D., Zemmour, H., Moss, J., Magenheim, J., Vaknin-Dembinsky, A., Rubertsson, S., Nellgård, B., Blennow, K., Zetterberg, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519286113 · Cited by 610
Connick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., Du, M.-Q., Luan, S.-L., Altmann, D. R., Thompson, A. J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70305-2 · Cited by 607
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Inefficient clearance of myelin debris by microglia impairs remyelinating processes
Lampron, A., Larochelle, A., Laflamme, N., Préfontaine, P., Plante, M.-M., Sánchez, M. G., Yong, V. W., Stys, P. K., Tremblay, M.-È., & Rivest, S. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141656 · Cited by 595
Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota
Cignarella, F., Cantoni, C., Ghezzi, L., Salter, A., Dorsett, Y., Chen, L., Phillips, D., Weinstock, G. M., Fontana, L., Cross, A. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.006 · Cited by 568
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Multiple sclerosis: experimental models and reality
Lassmann, H., & Bradl, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1631-4 · Cited by 525
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski, A., Ruhrmann, S., Faigle, W., Frauenknecht, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.011 · Cited by 508
MAFG-driven astrocytes promote CNS inflammation
Wheeler, M. A., Clark, I. C., Tjon, E. C., Li, Z., Zandee, S. E. J., Couturier, C. P., Watson, B. R., Scalisi, G., Alkwai, S., Rothhammer, V., et al. (2020) · Nature · doi:10.1038/s41586-020-1999-0 · Cited by 501
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Silent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
Deep gray matter volume loss drives disability worsening in multiple sclerosis
Eshaghi, A., Prados, F., Brownlee, W. J., Altmann, D. R., Tur, C., Cardoso, M. J., De Angelis, F., van de Pavert, S. H., Cawley, N., De Stefano, N., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25145 · Cited by 450
Forbes, J. D., Chen, C.-Y., Knox, N. C., Marrie, R.-A., El-Gabalawy, H., de Kievit, T., Alfa, M., Bernstein, C. N., & Van Domselaar, G. (2018) · Microbiome · doi:10.1186/s40168-018-0603-4 · Cited by 450
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0717-1 · Cited by 429
Cooperative, O. B. O. T. N., Sati, P., Oh, J., Constable, R. T., Evangelou, N., Guttmann, C. R. G., Henry, R. G., Klawiter, E. C., Mainero, C., Massacesi, L., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.166 · Cited by 426
on behalf of the MAGNIMS study group, Rovira, À., Wattjes, M. P., Tintoré, M., Tur, C., Yousry, T. A., Sormani, M. P., De Stefano, N., Filippi, M., Auger, C., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.106 · Cited by 423
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives
Lohrke, J., Frenzel, T., Endrikat, J., Alves, F. C., Grist, T. M., Law, M., Lee, J. M., Leiner, T., Li, K.-C., Nikolaou, K., et al. (2016) · Advances in Therapy · doi:10.1007/s12325-015-0275-4 · Cited by 420
Clinical Course of Multiple Sclerosis
Klineova, S., & Lublin, F. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028928 · Cited by 401
Self-citationEULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
Seror, R., Bowman, S. J., Brito-Zeron, P., Theander, E., Bootsma, H., Tzioufas, A., Gottenberg, J.-E., Ramos-Casals, M., Dörner, T., Ravaud, P., et al. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000022 · Cited by 398
Diffusion tensor imaging of post mortem multiple sclerosis brain
Schmierer, K., Wheeler-Kingshott, C. A. M., Boulby, P. A., Scaravilli, F., Altmann, D. R., Barker, G. J., Tofts, P. S., & Miller, D. H. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.010 · Cited by 395
Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four‐year study
Saidha, S., Al‐Louzi, O., Ratchford, J. N., Bhargava, P., Oh, J., Newsome, S. D., Prince, J. L., Pham, D., Roy, S., van Zijl, P., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24487 · Cited by 391
Zivadinov, R. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.6.773 · Cited by 385
Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10
Rojas, O. L., Pröbstel, A.-K., Porfilio, E. A., Wang, A. A., Charabati, M., Sun, T., Lee, D. S. W., Galicia, G., Ramaglia, V., Ward, L. A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.035 · Cited by 382
Erickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378
Progression of regional grey matter atrophy in multiple sclerosis
Eshaghi, A., Marinescu, R. V., Young, A. L., Firth, N. C., Prados, F., Jorge Cardoso, M., Tur, C., De Angelis, F., Cawley, N., Brownlee, W. J., et al. (2018) · Brain · doi:10.1093/brain/awy088 · Cited by 372
Harding, K., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T., Robertson, N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 366
Longitudinal multiple sclerosis lesion segmentation: Resource and challenge
Carass, A., Roy, S., Jog, A., Cuzzocreo, J. L., Magrath, E., Gherman, A., Button, J., Nguyen, J., Prados, F., Sudre, C. H., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.064 · Cited by 357
Haider, L., Simeonidou, C., Steinberger, G., Hametner, S., Grigoriadis, N., Deretzi, G., Kovacs, G. G., Kutzelnigg, A., Lassmann, H., & Frischer, J. M. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307712 · Cited by 357
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., Islam-Jakobsson, P., Malmeström, C., Axelsson, M., Vågberg, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003331 · Cited by 354
Multiple sclerosis: Pathology, diagnosis and treatments
Huang, W.-J., Chen, W.-W., & Zhang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4410 · Cited by 351
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?
Heesen, C. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065805 · Cited by 345
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Traboulsee, A., Simon, J. H., Stone, L., Fisher, E., Jones, D. E., Malhotra, A., Newsome, S. D., Oh, J., Reich, D. S., Richert, N., et al. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4539 · Cited by 340
Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum
Flanagan, E. P., Cabre, P., Weinshenker, B. G., Sauver, J. S., Jacobson, D. J., Majed, M., Lennon, V. A., Lucchinetti, C. F., McKeon, A., Matiello, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24617 · Cited by 338
The contemporary spectrum of multiple sclerosis misdiagnosis
Solomon, A. J., Bourdette, D. N., Cross, A. H., Applebee, A., Skidd, P. M., Howard, D. B., Spain, R. I., Cameron, M. H., Kim, E., Mass, M. K., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003152 · Cited by 334
Gut-licensed IFNγ+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes
Sanmarco, L. M., Wheeler, M. A., Gutiérrez-Vázquez, C., Polonio, C. M., Linnerbauer, M., Pinho-Ribeiro, F. A., Li, Z., Giovannoni, F., Batterman, K. V., Scalisi, G., et al. (2021) · Nature · doi:10.1038/s41586-020-03116-4 · Cited by 331
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses
Farez, M. F., Mascanfroni, I. D., Méndez-Huergo, S. P., Yeste, A., Murugaiyan, G., Garo, L. P., Balbuena Aguirre, M. E., Patel, B., Ysrraelit, M. C., Zhu, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.025 · Cited by 318
Prada, I., Gabrielli, M., Turola, E., Iorio, A., D’Arrigo, G., Parolisi, R., De Luca, M., Pacifici, M., Bastoni, M., Lombardi, M., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1803-x · Cited by 312
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00577 · Cited by 310
Exercise therapy for fatigue in multiple sclerosis
Heine, M., van de Port, I., Rietberg, M. B., van Wegen, E. E., & Kwakkel, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009956.pub2 · Cited by 307
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Muraro, P. A., Martin, R., Mancardi, G. L., Nicholas, R., Sormani, M. P., & Saccardi, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.81 · Cited by 304
Tourbah, A., Lebrun-Frenay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., De Sèze, J., Debouverie, M., Gout, O., Clavelou, P., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516667568 · Cited by 302
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
Absinta, M., Vuolo, L., Rao, A., Nair, G., Sati, P., Cortese, I. C. M., Ohayon, J., Fenton, K., Reyes-Mantilla, M. I., Maric, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001587 · Cited by 296
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Cercignani, M. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.3.311 · Cited by 291
Serum GFAP as a biomarker for disease severity in multiple sclerosis
Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., & Otto, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33158-8 · Cited by 291
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 289
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox, R. J., Coffey, C. S., Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803583 · Cited by 286
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
The Role of Natural Killer Cells in Autoimmune Diseases
Kucuksezer, U. C., Aktas Cetin, E., Esen, F., Tahrali, I., Akdeniz, N., Gelmez, M. Y., & Deniz, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622306 · Cited by 284
Role of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation
Schmierer, K., Wheeler‐Kingshott, C. A. M., Tozer, D. J., Boulby, P. A., Parkes, H. G., Yousry, T. A., Scaravilli, F., Barker, G. J., Tofts, P. S., & Miller, D. H. (2008) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21487 · Cited by 281
Age and disability accumulation in multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Ebers, G. C., & Muraro, P. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a17d · Cited by 279
Commowick, O., Istace, A., Kain, M., Laurent, B., Leray, F., Simon, M., Pop, S. C., Girard, P., Améli, R., Ferré, J.-C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31911-7 · Cited by 277
Zamvil, S. S., & Slavin, A. J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000062 · Cited by 276
Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment
Haki, M., AL-Biati, H. A., Al-Tameemi, Z. S., Ali, I. S., & Al-hussaniy, H. A. (2024) · Medicine · doi:10.1097/md.0000000000037297 · Cited by 274
Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain
Schmierer, K., Tozer, D. J., Scaravilli, F., Altmann, D. R., Barker, G. J., Tofts, P. S., & Miller, D. H. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20984 · Cited by 273
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Digital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 272
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study
Lunde, H. M. B., Assmus, J., Myhr, K.-M., Bø, L., & Grytten, N. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315238 · Cited by 269
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
Tutuncu, M., Tang, J., Zeid, N. A., Kale, N., Crusan, D. J., Atkinson, E. J., Siva, A., Pittock, S. J., Pirko, I., Keegan, B. M., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512451510 · Cited by 267
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
The Role of Astrocytes in Multiple Sclerosis Progression
Correale, J., & Farez, M. F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00180 · Cited by 261
Hawkins, S. A., & McDonnell, G. V. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.2.148 · Cited by 260
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Neuropsychological Aspects of Multiple Sclerosis
Brassington, J. C., & Marsh, N. V. (1998) · Neuropsychology Review · doi:10.1023/a:1025621700003 · Cited by 258
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Eshaghi, A., Young, A. L., Wijeratne, P. A., Prados, F., Arnold, D. L., Narayanan, S., Guttmann, C. R. G., Barkhof, F., Alexander, D. C., Thompson, A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22265-2 · Cited by 257
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Short Myelitis Lesions in Aquaporin-4-IgG–Positive Neuromyelitis Optica Spectrum Disorders
Flanagan, E. P., Weinshenker, B. G., Krecke, K. N., Lennon, V. A., Lucchinetti, C. F., McKeon, A., Wingerchuk, D. M., Shuster, E. A., Jiao, Y., Horta, E. S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2137 · Cited by 249
Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value
Kearney, H., Miller, D. H., & Ciccarelli, O. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.80 · Cited by 235
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Kim, S.-M., Woodhall, M. R., Kim, J.-S., Kim, S.-J., Park, K. S., Vincent, A., Lee, K.-W., & Waters, P. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000163 · Cited by 232
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228
Self-citationAlemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004313 · Cited by 221
Metadata
- Authors
- Lublin, F. D.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 72
- Issue
- Suppl. 1
- Pages
- 1-5
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2142577589
- Cited by
- 4,259
- References
- 5
- FWCI
- 267.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.